ID   1383D2-B2M-KO #1
AC   CVCL_C1FK
SY   1383D2-B2M-#1
DR   Wikidata; Q114310347
RX   Patent=US20200407693;
RX   PubMed=30853558;
CC   Population: Asian.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_UP38 ! 1383D2
SX   Male
AG   36Y
CA   Induced pluripotent stem cell
DT   Created: 22-09-22; Last updated: 29-06-23; Version: 4
//
RX   Patent=US20200407693;
RA   Hotta A., Xu H.-G., Kaneko S., Wang B.;
RT   "Method for producing low-antigenic cell.";
RL   Patent number US20200407693, 31-Dec-2020.
//
RX   PubMed=30853558; DOI=10.1016/j.stem.2019.02.005;
RA   Xu H.-G., Wang B., Ono M., Kagita A., Fujii K., Sasakawa N., Ueda T.,
RA   Gee P., Nishikawa M., Nomura M., Kitaoka F., Takahashi T., Okita K.,
RA   Yoshida Y., Kaneko S., Hotta A.;
RT   "Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with
RT   enhanced immune compatibility.";
RL   Cell Stem Cell 24:566-578.e7(2019).
//